As a potent driver of neurogenesis, and clinical marker of NEPC9, persistent hASH1 localisation could maintain expression of the transcriptional programs that give rise to NEPC therapeutic resistance and potentially initiate more rapid NE transdifferentiation upon subsequent AD, suggesting iADT may promote aggressive NEPC evolution. This evidence concerns the gene ASCL1 and Alzheimer disease.